D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
O GefvertL Lindström

Abstract

Quetiapine is a novel antipsychotic agent with many atypical features, including low D(2) and higher 5HT(2A) affinity in vitro, low propensity to induce extra-pyramidal side effects and minimal effects on prolactin levels. The purpose of this study was to investigate, using positron emission tomography (PET), the relationship between plasma concentrations of different doses of quetiapine and occupancy of D(2) and 5HT(2A) receptors in schizophrenic patients. Five patients were treated with quetiapine (titrated to 750 or 450 mg/day) for 28 days, subsequently reduced weekly in a descending-dose schedule. Dopamine D(2) and 5HT(2A) occupancies were determined using [(11)C] raclopride and [(11)C] N-methylspiperone as ligands, respectively, and PET imaging. Mean D(2) receptor occupancies of 41 and 30% were observed at quetiapine doses of 750 and 450 mg/day. At lower dose levels no occupancy could be determined. Quetiapine induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 and 450 mg/day, respectively. No EPS emerged during the trial and most of the pre-trial EPS resolved during the study. In clinically effective doses, quetiapine induced low occupancy at D(2) recepto...Continue Reading

References

Oct 1, 1989·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·L FardeC Halldin
Dec 1, 1985·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·C S Patlak, R G Blasberg
Sep 1, 1996·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·J LoganD L Alexoff
Nov 14, 1997·Acta Psychiatrica Scandinavica·J Peuskens, C G Link

❮ Previous
Next ❯

Citations

Jan 2, 2003·Annals of Nuclear Medicine·W Gordon Frankle, Marc Laruelle
Sep 29, 2011·Pflügers Archiv : European journal of physiology·Jeffrey M Ellenbogen, Edward F Pace-Schott
Jan 13, 2006·Journal of Pharmacokinetics and Pharmacodynamics·Mats BergströmBengt Långström
Apr 15, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Lefteris LykourasAndreas Rabavilas
Dec 7, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Peter S Talbot, Marc Laruelle
Mar 26, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Lefteris LykourasJohn Hatzimanolis
Apr 18, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mei HuangHerbert Y Meltzer
Oct 21, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gerhard GründerPeter Bartenstein
Sep 27, 2003·The Australian and New Zealand Journal of Psychiatry·Isabella PacchiarottiRoberto Tatarelli
Apr 19, 2003·International Clinical Psychopharmacology·Stéphane PotvinJean-Yves Roy
May 24, 2007·International Clinical Psychopharmacology·Thomas J RaedlerKlaus Wiedemann
Oct 28, 2008·Psychiatry and Clinical Neurosciences·Ying-Yeh ChenKevin Chien-Chang Wu
Apr 1, 2007·Neuropsychiatric Disease and Treatment·Michael RiedelHans-Jürgen Möller
Apr 24, 2012·CNS Drugs·Mark Sanford, Gillian M Keating
Sep 25, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nelleke TolboomArvid Carlsson
Jun 24, 2006·Drug Discovery Today·Kurt Rasmussen
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Roger S McIntyreJakub Z Konarski
Nov 13, 2002·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Saeeduddin AhmedWilliam Z Potter
May 17, 2014·The International Journal of Neuropsychopharmacology·Hans RasmussenBirte Glenthøj
Apr 16, 2010·The International Journal of Neuropsychopharmacology·Ingo VernalekenGerhard Gründer
Sep 6, 2008·Progress in Brain Research·Toshihide KurokiTatsuo Nakahara
Jul 29, 2016·The International Journal of Neuropsychopharmacology·Lars MichelsAnnette B Brühl
Sep 11, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chia-Hui ChenMing-Chyi Huang
Aug 1, 2009·Expert Opinion on Drug Discovery·Gianluca NucciItalo Poggesi
Jan 14, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Qiaozhen ChenMei Tian
Oct 6, 2005·Journal of Psychopharmacology·Peter J Weiden
Oct 8, 2008·Journal of Psychopharmacology·Luísa W Bisol, Diogo R Lara
Jul 2, 2004·Therapeutic Drug Monitoring·Christoph HiemkeMatthias J Müller
Oct 10, 2007·Harvard Review of Psychiatry·W Gordon Frankle
Jan 16, 2017·Journal of Psychiatric Research·So KirinoHiroyuki Uchida
Mar 1, 2008·Journal of Psychopharmacology·A M CatafauUNKNOWN Barcelona Clinical Imaging in Psychiatry Group
Jul 21, 2006·Journal of Clinical Psychopharmacology·Sophia Stamouli, Lefteris Lykouras
Nov 18, 2008·Journal of Clinical Psychopharmacology·Young-Min ParkSeung-Gul Kang
Aug 13, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Emmanouil RizosLefteris P Lykouras
Nov 27, 2019·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hideaki TaniHiroyoshi Takeuchi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here